Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis

Anticancer Research(2024)10.21873/anticanres.17248Source: DataRank Database

Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis is a research paper published in Anticancer Research (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.68)OA: hybridTopics (76)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Islauddin Khan ORCID,Matheus Hikaru Tanimoto ORCID,Jennyfer Andrea Aldana Mejía ORCID,Aline Mayrink de Miranda ORCID,Arun K. Rishi ORCID

Live enrichment

PubMed:39348999 PMC:PMC11863775 OpenAlex:https://openalex.org/W4402987445

NIMHD NIH HHS

Grant: U54 MD007582

National Institutes of Health

Grant: 5U54MD007582-37

FAMU Center for Health Disparities Research

FWCI

2.68

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://ar.iiarjournals.org/content/anticanres/44/10/4175.full.pdf

publisherhttps://ar.iiarjournals.org/content/anticanres/44/10/4175.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.21873/anticanres.17248

journalhttps://doi.org/10.21873/anticanres.17248

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39348999

Fields of Study

Natural Compound Pharmacology StudiesBioactive Compounds and Antitumor AgentsSynthesis and bioactivity of alkaloids03 medical and health sciences0302 clinical medicineHumansAnimalsLung NeoplasmsApoptosisDrug Resistance, NeoplasmCell Line, TumorAniline CompoundsMiceAcrylamidesXenograft Model Antitumor AssaysMice, NudeMice, Inbred BALB CErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsBenzophenonesCell SurvivalIndolesPyrimidines

MeSH Terms

AcrylamidesAniline CompoundsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzophenonesCell SurvivalHumansIndolesLung NeoplasmsMice, Inbred BALB CMice, NudePyrimidinesApoptosisDrug Resistance, NeoplasmXenograft Model Antitumor AssaysCell Line, TumorMiceErbB Receptors

Keywords

CarboplatinOsimertinibLung cancerApoptosisMedicineCancer researchCancerInternal medicineChemotherapyOncologyAdenocarcinomaBiologyCisplatinPARPPD-L1SIRT1Guttiferone EAcrylamidesMice, Inbred BALB CLung NeoplasmsAniline CompoundsIndolesCell SurvivalMice, NudeXenograft Model Antitumor AssaysArticleErbB ReceptorsMiceBenzophenonesPyrimidinesDrug Resistance, NeoplasmCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansAnimals

Sustainable Development Goals

SDG 0: Good health and well-being

Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis

FAIR Checklist

Authors (9)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)